Harmony Biosciences Holdings (HRMY) Price & Analysis

Compare

313 Followers

HRMY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$26.47 - $41.61

Previous CloseN/A

Volume87.33K

Average Volume (3M)595.00K

Market Cap

$2.01B

Enterprise Value$1.49B

Total Cash (Recent Filing)$546.05M

Total Debt (Recent Filing)$18.75M

Price to Earnings (P/E)11.3

Beta1.53

Next Earnings

Nov 04, 2025

EPS Estimate

0.74

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.68

Shares Outstanding57,424,320

10 Day Avg. Volume623,835

30 Day Avg. Volume594,998

Financial Highlights & Ratios

PEG Ratio0.75

Price to Book (P/B)2.97

Price to Sales (P/S)2.74

P/FCF Ratio8.95

Enterprise Value/Market Cap0.74

Enterprise Value/Revenue1.93

Enterprise Value/Gross Profit2.46

Enterprise Value/Ebitda5.87

Forecast

1Y Price Target

$52.67

Price Target Upside50.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical ValidationThe outcome of Takeda's trials provides a clear clinical and mechanistic readthrough to Harmony’s BP1.15205 program, highlighting its potential.

Market OpportunityThe potential market for ZYN-002 is large, with a total addressable market of over $2 billion and no FDA approved treatments currently available.

Pipeline ExpansionHarmony is entering a catalyst-rich era with a confident outlook for its next wave of growth.

Bears Say

Investor ExpectationsInvestor expectations are low for Harmony Biosciences due to a history of failures, gel formulation issues, and an unproven mechanism of action.

Placebo RiskThere is a risk of high placebo response impacting the success of ZYN-002 in Fragile X Syndrome.

RevenueWakix sales for 2Q came in at $200.5M slightly lower than consensus of $204.1.

Harmony Biosciences Holdings News

3 Best Stocks to Buy Now, 8/6/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1d ago

HRMY

SNDX

Harmony Biosciences backs FY25 revenue view $820M-$860M, consensus $843.63M

The company said, “Reaffirming full year 2025 net product revenue of $820 million to $860 million.” Published first...

2d ago

HRMY

Harmony Biosciences reports Q2 adjusted EPS 92c, consensus 96c

Reports Q2 revenue $200.49M, consensus $204.12M. “The approximately 80,000 U.S. families in the Fragile X community have been...

2d ago

HRMY

3 Best Stocks to Buy Now, 7/29/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

9d ago

DNTH

HRMY

Harmony Biosciences initiated with a Buy at Truist

Truist initiated coverage of Harmony Biosciences (HRMY) with a Buy rating and $48 price target Truist sees unrealized...

17d ago

HRMY

Harmony Biosciences price target raised to $55 from $54 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $55 from $54 and keeps a...

28d ago

HRMY

Harmony Biosciences resumed with a Neutral at Goldman Sachs

Goldman Sachs analyst Corinne Johnson resumed coverage of Harmony Biosciences (HRMY) with a Neutral rating and $33 price...

28d ago

HRMY

Harmony Biosciences: Buy Rating Affirmed on Strong Growth Prospects and Strategic Advancements

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Harmony Biosciences Holdings today and set a price...

1d ago

HRMY

Harmony Biosciences Earnings Call Highlights Growth and Innovation

Harmony Biosciences Holdings, Inc. (($HRMY)) has held its Q2 earnings call. Read on for the main highlights of...

2d ago

HRMY

Harmony Biosciences Holdings: Strong Patient Growth and Promising Pipeline Support Buy Rating

Analyst Ami Fadia of Needham maintained a Buy rating on Harmony Biosciences Holdings, retaining the price target of...

2d ago

HRMY

Harmony Biosciences Holdings: Promising Growth Trajectory with Strong Leadership and Robust Pipeline Supports Buy Rating

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Harmony Biosciences Holdings,...

17d ago

HRMY

Buy Rating Reaffirmed for Harmony Biosciences Amid Promising Orexin-2 Developments and Takeda’s Phase 3 Success

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Harmony Biosciences Holdings, retaining the price target...

23d ago

HRMY

Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205

Harmony Biosciences Holdings ( ($HRMY) ) just unveiled an update. On June 11, 2025, Harmony Biosciences announced new...

2M ago

HRMY

Harmony Biosciences presents preclinical data for BP1.15205

Harmony Biosciences (HRMY) announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and...

2M ago

HRMY

HRMY FAQ

What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?

Harmony Biosciences Holdings, Inc. lowest stock price was $26.47 and its highest was $41.61 in the past 12 months.

What is Harmony Biosciences Holdings, Inc.’s market cap?

Harmony Biosciences Holdings, Inc.’s market cap is $2.01B.

When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?

Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Nov 04, 2025 which is in 89 days.

How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?

Harmony Biosciences Holdings, Inc. released its earnings results on Jul 31, 2025. The company reported $0.68 earnings per share for the quarter, missing the consensus estimate of $0.705 by -$0.025.

Is Harmony Biosciences Holdings, Inc. overvalued?

According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Harmony Biosciences Holdings, Inc. pay dividends?

Harmony Biosciences Holdings, Inc. does not currently pay dividends.

What is Harmony Biosciences Holdings, Inc.’s EPS estimate?

Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.74.

How many shares outstanding does Harmony Biosciences Holdings, Inc. have?

Harmony Biosciences Holdings, Inc. has 57,424,320 shares outstanding.

What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?

Harmony Biosciences Holdings, Inc. reported an EPS of $0.68 in its last earnings report, missing expectations of $0.705. Following the earnings report the stock price went down -0.846%.

Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?

Currently, no hedge funds are holding shares in HRMY

Harmony Biosciences Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

27.58%

Trailing 12-Months

Asset Growth

29.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological disorders. The company is primarily engaged in the healthcare sector, with its core product being WAKIX (pitolisant), a novel treatment for excessive daytime sleepiness in adults with narcolepsy.

Harmony Biosciences Holdings (HRMY) Earnings & Revenues

Historic Earnings Reports

HRMY Company Deck

HRMY Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook, highlighting strong revenue growth and significant advancements in the company's pipeline. Although there were some concerns regarding inventory fluctuations and potential regulatory challenges, the company's robust financial position and strategic collaborations suggest continued growth and innovation.View all HRMY earnings summaries

HRMY Stock 12 Month Forecast

Average Price Target

$52.67

▲(50.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","71":"$71","38.75":"$38.8","49.5":"$49.5","60.25":"$60.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,38.75,49.5,60.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.4,37.138461538461534,39.87692307692308,42.61538461538461,45.35384615384615,48.09230769230769,50.83076923076923,53.56923076923077,56.30769230769231,59.04615384615384,61.784615384615385,64.52307692307693,67.26153846153846,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.4,35.80538461538461,37.21076923076923,38.61615384615384,40.02153846153846,41.426923076923075,42.832307692307694,44.237692307692306,45.643076923076926,47.04846153846154,48.45384615384616,49.85923076923077,51.26461538461538,{"y":52.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.4,34.29230769230769,34.184615384615384,34.07692307692307,33.96923076923077,33.86153846153846,33.753846153846155,33.646153846153844,33.53846153846154,33.43076923076923,33.323076923076925,33.215384615384615,33.10769230769231,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.24,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.41,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >